Tova Gardin

Chief Translational Officer
Biohaven

Dr. Tova Gardin is a physician-scientist and translational R&D leader, and Chief Translational Officer at Biohaven (NYSE: BHVN), where she leads the company’s first-in-class MoDE and TRAP extracellular protein degrader platform. Under her leadership, the platform has grown to multiple key therapeutic areas and has advanced from discovery through first-in-patient data and into pivotal Phase 3 development. Her work bridges mechanistic biology, clinical development, strategy, and execution.

Dr. Gardin earned her MD with honors in research from Harvard Medical School and an MPP from Princeton University. She completed residency training in neurology and psychiatry and a neuroimmunology fellowship at Yale and is the founder of the Yale Autoimmune Encephalitis Program.